Liquidia Corporation

NasdaqCM:LQDA Stock Report

Market Cap: US$5.1b

Liquidia Future Growth

Future criteria checks 5/6

Liquidia is forecast to grow earnings and revenue by 29.7% and 25.3% per annum respectively while EPS is expected to grow by 29.2% per annum.

Key information

29.7%

Earnings growth rate

29.21%

EPS growth rate

Pharmaceuticals earnings growth11.9%
Revenue growth rate25.3%
Future return on equityn/a
Analyst coverage

Good

Last updated12 May 2026

Recent future growth updates

Recent updates

Analysis Article • May 13

Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts

Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...
Seeking Alpha • Jan 06

Liquidia: Big Q3 Sales Print, But Voucher Starts And Inventory Can Distort Optics

Summary Liquidia (LQDA) has rebounded with YUTREPIA's FDA approval and $51.7M in Q3 net product sales, but valuation remains fragile. Current sales and script numbers are influenced by channel inventory, GTN estimates, and free voucher programs, casting uncertainty on true patient demand and revenue durability. Litigation risk persists, particularly regarding United Therapeutics' patents, with outcomes that could significantly impact YUTREPIA's commercial footprint. I maintain a Sell rating on LQDA, citing unresolved litigation, uncertain real-world uptake, and a valuation that prices in substantial future success. Read the full article on Seeking Alpha
Analysis Article • Dec 06

Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump

Liquidia Corporation ( NASDAQ:LQDA ) shares have had a really impressive month, gaining 30% after a shaky period...
Analysis Article • Aug 09

Is Liquidia (NASDAQ:LQDA) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Jan 31

Liquidia Corporation's Long-Running Saga Is Coming To An End

Summary Today, we are circling back on Liquidia Corporation, as its long-running litigation battle with United Therapeutics is finally coming to a positive end. This means we will likely see the full commercial launch of its primary candidate, YUTREPIA before the end of the second market. YUTREPIA is targeting a large potential market and could garner significant market share. An updated analysis around Liquidia Corporation follows in the paragraphs below. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqCM:LQDA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,3476486196135
12/31/20271,1725935405357
12/31/20267053363942857
3/31/2026288223948N/A
12/31/2025158-69-42-36N/A
9/30/202569-124-108-101N/A
6/30/202519-152-124-116N/A
3/31/202514-137-107-99N/A
12/31/202414-128-102-93N/A
9/30/202416-117-92-89N/A
6/30/202415-102-88-75N/A
3/31/202416-97-70-58N/A
12/31/202317-79-53-42N/A
9/30/202318-58-42-30N/A
6/30/202318-51-26-24N/A
3/31/202317-37-28-27N/A
12/31/202216-41-29-29N/A
9/30/202214-46-32-32N/A
6/30/202214-44-32-32N/A
3/31/202213-41-31-31N/A
12/31/202113-35-34-34N/A
9/30/202110-39-41-41N/A
6/30/20217-47-47-47N/A
3/31/20214-54-53-52N/A
12/31/20201-60-55-54N/A
9/30/2020N/A-58-55-54N/A
6/30/2020N/A-57-55-54N/A
3/31/20208-49-54-53N/A
12/31/20198-48N/A-48N/A
9/30/20199-43N/A-43N/A
6/30/20199-39N/A-37N/A
3/31/20192-39N/A-32N/A
12/31/20183-53N/A-32N/A
9/30/20184-35N/A-28N/A
6/30/20186-45N/A-27N/A
3/31/20187-47N/A-25N/A
12/31/20177-29N/A-24N/A
12/31/201613-16N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LQDA's forecast earnings growth (29.7% per year) is above the savings rate (3.5%).

Earnings vs Market: LQDA's earnings (29.7% per year) are forecast to grow faster than the US market (16.7% per year).

High Growth Earnings: LQDA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: LQDA's revenue (25.3% per year) is forecast to grow faster than the US market (11.6% per year).

High Growth Revenue: LQDA's revenue (25.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LQDA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 05:04
End of Day Share Price 2026/05/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Liquidia Corporation is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Julian HarrisonBTIG
Andrew FeinH.C. Wainwright & Co.